Publications

TOURRET M ET AL., 2021 

Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy. Journal for ImmunoTherapy of Cancer.

PIPEROGLOU C, LARID G, VALLENTIN B, ET AL., 2021

Innate lymphoid cell recovery and occurrence of GvHD after hematopoietic stem cell transplantation. J Leukoc Biol. 

LATIS E. ET AL., 2020

Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD. Blood Advances. 

ROBERT E. ET AL, 2020

“CRYOSTEM Biobank: A National Prospective, Standardized Collection to Better Characterize Allogeneic Hematopoietic Stem Cell Transplantation Complications”. Open Journal of Bioresources. 

MICHONNEAU D. ET AL., 2019

Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites. Nature Communications. 

DE MASSON A. ET AL., 2015

CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood. 

SOCIÉ G. ET AL., 2014

Current issues in chronic graft-versus-host disease. Blood. 

DONG S. ET AL., 2013

Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease. Blood. 

RODRIGUEZ-OTERO P. ET AL., 2012

Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. Blood. 

HIPPEN KL. ET AL., 2012

Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood. 

SOCIE G ET AL., 2011

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 

WINGARD JR. ET AL., 2011

Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol.